GT Bio's CEO Michael Breen said he's seen "encouraging trends" in ongoing AML Phase I trials that could validate the platform's efficacy as the company moves into solid tumors. The firm's leadership ...
Researchers at Karolinska Institutet have uncovered a unique ability of a special subtype of natural killer cells in the immune system, called adaptive NK cells, to remember ovarian tumors and ...
CytomX Therapeutics (Nasdaq: CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today entered into a collaboration with The University of ...
Hosted on MSN
Engineered CAR-NK cells could evade immune rejection and target cancer more effectively
One of the newest weapons that scientists have developed against cancer is a type of engineered immune cell known as CAR-NK (natural killer) cells. Similar to CAR-T cells, these cells can be ...
Recent press releases from two new partners of NextGenNK highlight important advances in natural killer (NK) cell-based immunotherapies, spanning both ...
One of the newest weapons that scientists have developed against cancer is a type of engineered immune cell known as CAR-NK (natural killer) cells. Similar to CAR-T cells, these cells can be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results